AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

HIV Gene Therapy Treatment

Technology Benefits: Potential to cure infected patients without the need of ongoing treatments or the use of expensive laboratory or clinical equipmentCould be made accessible to doctors and patients without specialized facilities, particularly those in developing countries where HIV infection is widespread

Technology Application: Curative gene therapy for HIV infection

Detailed Technology Description: Currently, HIV patients must undergo chronic drug treatments and often suffer adverse side effects to manage their disease. Researchers at the University of California, Davis have developed a novel HIV gene therapy that specifically targets those cells in a patient that are susceptible to infection. Current methods of HIV gene therapy require the removal and isolation of specific cells from the patient, introduction of the therapeutic vector into the cells, and administration of these cells back into the patient. This new technology would allow the introduction of the vector directly into the patient without the need of removing and isolating cells in a laboratory or clinic. Another significant advantage of this HIV gene therapy is its potential to actually cure the disease. The standard treatment for HIV patients consists of a small molecule drug cocktail that must be taken throughout the patient's life to inhibit the replication of the virus. With the proposed therapy, anti-HIV genes are integrated into the target cells' genomes rendering them immune to infection. If enough target cells are successfully treated, the patient could potentially be cured of the infection. The HIV gene therapy uses recognition of an HIV receptor on the surface of host cells to identify which cells are susceptible to infection. Once recognized, these target cells are transduced with anti-HIV genes that prevent the replication and transmission of the virus.

Supplementary Information: Patent Number: US8728458B2
Application Number: US13266236A
Inventor: Anderson, Joseph | Bauer, Gerhard | Nolta, Jan A.
Priority Date: 30 Apr 2009
Priority Number: US8728458B2
Application Date: 2 Dec 2011
Publication Date: 20 May 2014
IPC Current: A61K004800
US Class: 42409321 | 4353201 | 435325 | 514044A | 43532001 | 514044
Assignee Applicant: The Regents of the University of California
Title: Combination anti-HIV vectors, targeting vectors, and methods of use
Usefulness: Combination anti-HIV vectors, targeting vectors, and methods of use
Summary: The lentiviral vector, the pseudotyped lentiviral vector particle, or the cell is useful for treating an HIV infection in a subject or for manufacturing a medicament to treat an HIV infection in a subject (all claimed).
Novelty: New lentiviral vector comprises a lentiviral backbone and a nucleic acid encoding CCR5 RNA interference, tripartite motif-containing 5 alpha sequence, and HIV trans-activating response region sequence, useful for treating HIV infection